Results 71 to 80 of about 2,966,592 (306)

Virtual Interviews for the Complex General Surgical Oncology Fellowship: The Dana-Farber/Partners Experience

Annals of Surgical Oncology, 2020
George Molina, MD, MPH, Winta T. Mehtsun, MD, MPH, Motaz Qadan, MD, PhD, Keisha C. Hause, MHA, Chandrajit P. Raut, MD, MSc, and Mark Fairweather, MD Division of Surgical Oncology, Department of Surgery, Harvard Medical School, Brigham and Women’s ...
G. Molina, W. Mehtsun, M. Qadan, Keisha C. Hause, C. Raut, M. Fairweather   +5 more
semanticscholar   +1 more source

Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms

BMC Cancer, 2023
Background Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that converts tryptophan to kynurenine. IDO1 expression is found not only in tumor cells but also in immune cells and is associated with tumor proliferation and immune responses.
Hiroaki Nozawa, Tetsuro Taira, Hirofumi Sonoda, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Shinya Abe, Soichiro Ishihara   +9 more
doaj   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden

BMC Cancer, 2017
Background The tumor immune environment not only modulates the effects of immunotherapy, but also the effects of other anticancer drugs and treatment outcomes.
Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Shuhei Tomita, Hisashi Motomura, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira   +13 more
doaj   +1 more source

Dermatofibrosarcoma Protuberans of the Forehead: Case Report of a Rare Entity and Review of Literature

Case Reports in Oncological Medicine
Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma originating from fibroblasts in the dermal connective tissue, comprising approximately 1% of all soft tissue sarcomas.
Ulrich Igor Mbessoh Kengne, Jaafar Ibn Abou Talib Thiam, Amacoumba Fall, Salif Balde, Mamadou Ndiaye, Joel Gabin Konlack Mekontso, Gorgui Sarr, Etienne Tossou Zoure, Mamadou Sow, Sidy Ka   +9 more
doaj   +1 more source

Benefits of a laparoscopic approach for second colorectal resection after colectomy or proctectomy –a retrospective study-

BMC Surgery, 2023
Background A laparoscopic approach generally provides several benefits in patients who undergo colon or rectal surgery without jeopardizing oncological outcomes.
Hiroaki Nozawa, Kazuto Sasaki, Shigenobu Emoto, Koji Murono, Yuichiro Yokoyama, Hirofumi Sonoda, Yuzo Nagai, Shinya Abe, Soichiro Ishihara   +8 more
doaj   +1 more source

Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma [PDF]

, 2019
BACKGROUND: Meningiomas are the most common primary tumors of the central nervous system. In patients with WHO grade I meningiomas no adjuvant therapy is recommended after resection.
Acker, Güliz, Badakhshi, Harun, Budach, Volker, Ghadjar, Pirus, Grün, Arne, Hemmati, Saman Moritz, Kaul, David, Misch, Martin, Senger, Carolin, Zschaeck, Sebastian   +9 more
core   +1 more source

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures

JAMA Network Open, 2019
Key Points Question What are the morbidity and mortality of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) compared with other major oncologic surgical procedures?
J. Foster, R. Sleightholm, Asish Patel, V. Shostrom, B. Hall, B. Neilsen, D. Bartlett, Lynette M. Smith   +7 more
semanticscholar   +1 more source

COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission

Annals of Surgical Oncology, 2020
Background The global pandemic of respiratory disease cause by the novel human coronavirus (SARS-CoV-2) has caused untold suffering, loss of life and upheaval in society.
T. Pawlik, D. Tyler, B. Sumer, F. Meric-Bernstam, Ikenna C. Okereke, J. Beane, Priya H. Dedhia, A. Ejaz, K. McMasters, K. Tanabe   +9 more
semanticscholar   +1 more source

Single institution implementation of permanent 131Cs interstitial brachytherapy for previously irradiated patients with resectable recurrent head and neck carcinoma [PDF]

, 2019
Purpose: Permanent interstitial brachytherapy is an appealing treatment modality for patients with locoregional recurrent, resectable head and neck carcinoma (HNC), having previously received radiation.
Bar-Ad, Voichita, Cognetti, David, Curry, Joseph, Doyle, Laura, Harrison, Amy, Hubley, Emily, Johnson, Jennifer, Keller, James, Luginbuhl, Adam, Peng, Cheng, To, David   +10 more
core   +1 more source